In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioKine Inc.

Division of Chiesi Farmaceutici SPA
www.cardiokine.com

Latest From CardioKine Inc.

Chiesi Prepared To Pay Cash For Remaining 40% Of Cornerstone

Italian pharmaceutical company Chiesi is looking to buy up the remainder of Cornerstone Therapeutics, a company that already markets Chiesi’s products in the U.S. and is financially linked with the company.

BioPharmaceutical Business Strategies

CRO Chiltern names Roger Hunter VP

Roger Hunter

US FDA rebuffs Cornerstone electrolyte disorder drug lixivaptan

Perhaps it was the fact that investors expected a US FDA rejection following the negative outcome of a September advisory committee meeting – or that Wall Street remained in shock, recovering from Hurricane Sandy – but shares of Cornerstone Therapeutics had only a somewhat mild reaction to regulators calling for more data before approving the company's experimental drug lixivaptan.

Cardiovascular Dermatology

US FDA reviewer backs one lixivaptan use, but not other

Shares of Cornerstone Therapeutics rose as high as 7% on 11 September after a US FDA drug reviewer said an argument could be made for approval of lixivaptan, an orally-active, selective vasopressin 2 receptor antagonist, as a treatment for hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion, or SIADH, based on the currently available information, as long as the therapy is restricted to inpatient initiation.

Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Chiesi Farmaceutici SPA
  • Senior Management
  • Amber Salzman, PhD, Pres. & CEO
    Mark Guerin, VP, Fin. & CFO
    Cesare Orlandi, MD, SVP, Clinical Dev. & CMO
    Len Selihar, VP, Alliance Mgmt. & Corp. Dev.
  • Contact Info
  • CardioKine Inc.
    Phone: (215) 399-1200
    30 South 15th St.
    15th Fl.
    Philadelphia, PA 19102
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register